Madison-based cancer diagnostics startup Elephas Biosciences Corp. has raised $41.5 million in a Series B financing round as it prepares to launch two human clinical trials, the company announced Tuesday.

The startup is building a platform designed to determine whether a given type of therapy will work for a patient before their treatment begins. Its technology tests patient biopsies against different drugs, and uses advanced 3D imaging and artificial intelligence to predict their effectiveness.

Read the full article here